Skip to main content

Advertisement

Table 3 Classical prognostic factors and uPA and PAI-1 tumor tissue levels using standard reference cut-off values

From: Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy

Classical prognostic factors uPA (ng/mg of protein) PAI-1 (ng/mg of protein)
Values Categories Values Categories
Mean (SD) Median (Range) Wilcoxon rank sum ≤ 3 >  3 Pearson χ2 test Mean (SD) Median (Range) Wilcoxon rank sum ≤ 14 > 14 Pearson χ2 test
Tumor size
  ≤ 20 mm 3.9 (4.3) 2.5 (0.1–18.7) nsa 21 (51.2%) 13 (32.5%) nsb 17.7 (14.1) 12.5 (0.0–51.8) nsa 18 (56.3%) 16 (32.7%) nsb
 20–30 mm 4.9 (3.8) 4.0 (0.5–15.5) 15 (36.6%) 22 (55.0%) 24.6 (22.9) 17 (7.5–140) 10 (31.3%) 27 (55.1%)
  > 30 mm 4.3 (2.4) 5.1 (0.6–7.1) 4 (9.8%) 5 (12.5%) 24.6 (16.2) 24.5 (6.0–51.0) 3 (9.4%) 6 (12.2%)
 Unknown 1 (2.4%)   1 (3.1%)
Tumor grade
 Grade 1 4.1 (3.1) 5.2 (0.2–8.9) ns 5 (12.2%) 6 (15.0%) ns 20.4 (15.3) 18.6 (0.9–46.0) ns 5 (15.6%) 6 (12.2%) ns
 Grade 2/3 4.4 (4.0) 3 (0.1–18.7) 36 (87.8%) 34 (85.0%) 21.6 (19.5) 16.0 (0.0–140) 27 (84.4%) 43 (87.8%)
Estrogen receptor
  ≥ 50% 4.1 (3.6) 2.9 (0.2–15.5) ns 20 (48.8%) 18 (45.0%) ns 21.9 (23.0) 15.3 (0.9–140) ns 15 (46.9%) 23 (46.9%) ns
  < 50% 4.6 (5.2) 3.3 (0.1–18.7) 21 (51.2%) 22 (55.0%) 21.1 (14.6) 16.8 (0.0–56.8) 17 (53.1%) 26 (53.1%)
Ki67 index
  < 15% 3.8 (4.0) 1.8 (0.2–13.3) ns 14 (34.2%) 8 (20.0%) 0.039 17.0 (13.0) 13.8 (0.9–56.8) 0.038 11 (34.4%) 11 (22.5%) ns
  ≥ 15% 4.8 (3.4) 5.1 (0.5–15.5) 10 (24.4%) 19 (47.5%) 27.5 (25.3) 20.0 (3.0–140) 7 (21.9%) 22 (44.9%)
Unknown 17 (41.5%) 13 (32.5%) 14 (43.8%) 16 (32.7%)
Total 81 (100%) 41 (100%) 40 (100%) 81 (100%) 32 (100%) 49 (100%)
  1. aKruskal Wallis Test; bFisher exact test; ns-not statistically significant